These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29175174)

  • 41. Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature.
    Chen TJ; Lai PC; Yang LC; Kuo TT; Hong HS
    Am J Clin Dermatol; 2009; 10(3):197-200. PubMed ID: 19354335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid.
    Sach T
    Br J Dermatol; 2018 Feb; 178(2):320-321. PubMed ID: 29441558
    [No Abstract]   [Full Text] [Related]  

  • 43. Childhood Bullous Pemphigoid: A Treatment Challenge.
    Ayala-Cortés AS; Martínez-Cabriales SA; Welsh O; Rosales-Solis G; Vázquez-Martínez O; Ocampo-Candiani J
    J Pediatr; 2016 Dec; 179():271-271.e1. PubMed ID: 27697329
    [No Abstract]   [Full Text] [Related]  

  • 44. Sulfamethoxypyridazine-responsive pemphigoid nodularis: a report of two cases.
    Gach JE; Wilson NJ; Wojnarowska F; Ilchyshyn A
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S101-4. PubMed ID: 16021154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bullous pemphigoid treated with intravenous immunoglobulin.
    Tuchinda P; Ritchie S; Gaspari AA
    Cutis; 2014 May; 93(5):264-8. PubMed ID: 24897141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Localized bullous pemphigoid triggered by erysipelas].
    Löffel FB; Stücker M
    Hautarzt; 2016 Oct; 67(10):829-832. PubMed ID: 27341826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ecthyma-gangrenosum-like bullous pemphigoid.
    Geiss Steiner J; Trüeb RM; Kerl K; Mühleisen B; French LE; Hofbauer GF
    Dermatology; 2010; 221(2):142-8. PubMed ID: 20689254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment options for autoimmune bullous dermatoses other than systemic steroids: A systematic review and network meta-analysis.
    Salman S; Awad M; Sarsik S; Ibrahim AM; Fathi M; Agha NY; Anis R; El Ashal G; Salem ML
    Dermatol Ther; 2020 Nov; 33(6):e13861. PubMed ID: 32558137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bullous pemphigoid and related subepidermal autoimmune blistering diseases.
    Olasz EB; Yancey KB
    Curr Dir Autoimmun; 2008; 10():141-66. PubMed ID: 18460884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
    Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
    Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy.
    Fox JC; Kenkare S; Petronic-Rosic V; Soltani K; Sethi A
    Pediatr Dermatol; 2010; 27(5):537-9. PubMed ID: 20807355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita.
    Patel PM; Jones VA; Murray TN; Amber KT
    Am J Clin Dermatol; 2020 Aug; 21(4):557-565. PubMed ID: 32180161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bullous pemphigoid in childhood].
    Mensing H; Brehm H; Nasemann T
    Hautarzt; 1984 May; 35(5):254-8. PubMed ID: 6378831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Skin Hyperpigmentation and Melanonychia From Chronic Doxycycline Use.
    Dowlati E; Dovico J; Unwin B
    Ann Pharmacother; 2015 Oct; 49(10):1175-6. PubMed ID: 26228938
    [No Abstract]   [Full Text] [Related]  

  • 55. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
    Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
    J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients?
    Cardones AR; Hall RP
    Br J Dermatol; 2017 Nov; 177(5):1145-1147. PubMed ID: 29192991
    [No Abstract]   [Full Text] [Related]  

  • 57. Bullous pemphigoid treated by topical corticosteroids.
    Paquet P; Richelle M; Lapiere CM
    Acta Derm Venereol; 1991; 71(6):534-5. PubMed ID: 1685838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
    Joly P; Roujeau JC; Benichou J; Picard C; Dreno B; Delaporte E; Vaillant L; D'Incan M; Plantin P; Bedane C; Young P; Bernard P;
    N Engl J Med; 2002 Jan; 346(5):321-7. PubMed ID: 11821508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).
    Ujiie H; Iwata H; Yamagami J; Nakama T; Aoyama Y; Ikeda S; Ishii N; Iwatsuki K; Kurosawa M; Sawamura D; Tanikawa A; Tsuruta D; Nishie W; Fujimoto W; Amagai M; Shimizu H;
    J Dermatol; 2019 Dec; 46(12):1102-1135. PubMed ID: 31646663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.